The product is a therapeutic equal generic model of Prolixin tablets accepted by the US Food and Drug Administration (USFDA).
In a regulatory submitting, Dr Reddy’s laboratories introduced the launch of Fluphenazine Hydrochloride tablets in the US.
Quoting IQVIA Health knowledge, Dr Reddy’s stated Prolixin model and generic had US gross sales of roughly USD 134 million for the newest 12 months ending in December 2020.
Dr Reddy’s Fluphenazine Hydrochloride tablets, USP, can be found in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle depend sizes.
Shares of Dr Reddy’s Laboratories had been buying and selling 0.88 per cent larger at Rs 4,642.25 apiece on BSE.